Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -70.24% is 27% below its 5-year average of -55.49%, near the high end of its 5-year range (-586.56%–-27.17%).
As of the fiscal period ended Tuesday, June 30, 2026. 78.61% above its 12-month average of -328.40%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -70.24%.
RETURN ON EQUITY (ROE)
-70.24%
RETURN ON EQUITY (ROE) AVG TTM
-328.40%
RETURN ON EQUITY (ROE) AVG 3Y
-164.50%
RETURN ON EQUITY (ROE) AVG 5Y
-55.49%
RETURN ON EQUITY (ROE) AVG 10Y
-49.47%
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+78.61%
CURRENT VS 3Y AVG
+57.30%
CURRENT VS 5Y AVG
-26.59%
CURRENT VS 10Y AVG
-41.98%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-40.89%
median of 684 covered companies
CURRENT VS SECTOR MEDIAN
-71.78%
vs the sector median at left
Editas Medicine, Inc.
Market Cap
$435.06M
Return on Equity (ROE)
-70.24%
TTM Avg
-328.40%
3Y Avg
-164.50%
5Y Avg
-55.49%
Market Cap
$435.48M
Return on Equity (ROE)
-0.01%
TTM Avg
-61.70%
3Y Avg
-96.25%
5Y Avg
-81.28%
Market Cap
$440.73M
Return on Equity (ROE)
-52.56%
TTM Avg
-31.09%
3Y Avg
-101.75%
5Y Avg
-86.54%
Market Cap
$427.95M
Return on Equity (ROE)
-6.60%
TTM Avg
-10.82%
3Y Avg
-11.36%
5Y Avg
-7.59%
Market Cap
$444.52M
Return on Equity (ROE)
-160.85%
TTM Avg
-225.75%
3Y Avg
-186.61%
5Y Avg
-129.85%
Market Cap
$447.00M
Return on Equity (ROE)
-16.43%
TTM Avg
-26.04%
3Y Avg
-38.16%
5Y Avg
-45.00%
Market Cap
$422.13M
Return on Equity (ROE)
-1721.80%
TTM Avg
-73.40%
3Y Avg
-45.77%
5Y Avg
-18.46%
Market Cap
$448.71M
Return on Equity (ROE)
-97.92%
TTM Avg
-59.21%
3Y Avg
-49.84%
5Y Avg
-46.25%
Market Cap
$419.62M
Return on Equity (ROE)
-121.12%
TTM Avg
180.84%
3Y Avg
-1331.02%
5Y Avg
-839.91%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Editas Medicine, Inc. (EDIT) | $435.06M | -70.24% | -328.40% | -164.50% | -55.49% |
| Assembly Biosciences, Inc. (ASMB)vs › | $435.48M | -0.01% | -61.70% | -96.25% | -81.28% |
| Capricor Therapeutics, Inc. (CAPR)vs › | $440.73M | -52.56% | -31.09% | -101.75% | -86.54% |
| NeoGenomics, Inc. (NEO)vs › | $427.95M | -6.60% | -10.82% | -11.36% | -7.59% |
| NeuroPace, Inc. (NPCE)vs › | $444.52M | -160.85% | -225.75% | -186.61% | -129.85% |
| Ovid Therapeutics Inc. (OVID)vs › | $447.00M | -16.43% | -26.04% | -38.16% | -45.00% |
| ARS Pharmaceuticals, Inc. (SPRY)vs › | $422.13M | -1721.80% | -73.40% | -45.77% | -18.46% |
| DiaMedica Therapeutics Inc. (DMAC)vs › | $448.71M | -97.92% | -59.21% | -49.84% | -46.25% |
| Senseonics Holdings, Inc. (SENS)vs › | $419.62M | -121.12% | 180.84% | -1331.02% | -839.91% |
| Rezolute, Inc. (RZLT)vs › | $418.02M | -77.06% | -61.48% | -56.03% | -55.28% |
ROE
-70.2%
ROA
-31.1%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -70.24% |
| 2025-12-31 | -586.56% |
| 2025-03-31 | -402.48% |
| 2024-12-31 | -176.57% |
| 2024-09-30 | -119.89% |
| 2024-06-30 | -83.38% |
| 2024-03-31 | -56.43% |
| 2023-12-31 | -43.89% |
| 2023-09-30 | -54.12% |
| 2023-06-30 | -51.46% |
| 2023-03-31 | -68.97% |
| 2022-12-31 | -61.12% |
| 2022-09-30 | -48.49% |
| 2022-06-30 | -39.64% |
| 2022-03-31 | -36.33% |
| 2021-12-31 | -34.77% |
| 2021-09-30 | -36.40% |
| 2021-06-30 | -27.17% |
| 2021-03-31 | -21.16% |
| 2020-12-31 | -29.47% |
| 2020-09-30 | -20.68% |
| 2020-06-30 | -30.93% |
| 2020-03-31 | -60.63% |
| 2019-12-31 | -50.96% |
| 2019-09-30 | -57.64% |
| 2019-06-30 | -53.52% |
| 2019-03-31 | -49.85% |
| 2018-12-31 | -46.56% |
| 2018-09-30 | -53.95% |
| 2018-06-30 | -57.26% |
| 2018-03-31 | -48.55% |
| 2017-12-31 | -57.83% |
| 2017-09-30 | -69.47% |
| 2017-06-30 | -63.75% |
| 2017-03-31 | -53.54% |
| 2016-12-31 | -72.20% |
| 2016-09-30 | -41.39% |
| 2016-06-30 | -30.33% |
| 2016-03-31 | -42.39% |
| 2015-09-30 | -51.47% |
| 2015-06-30 | -437.76% |
| 2015-03-31 | -304.10% |
